Key terms
About VRDN
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VRDN news
Mar 24
9:40pm ET
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)
Mar 21
8:46am ET
Viridian Therapeutics price target lowered to $25 from $29 at B. Riley
Mar 21
6:40am ET
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)
Mar 20
3:35pm ET
Buy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market
Mar 20
2:35pm ET
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Competitive Position and Promising Drug Prospects
Mar 20
1:15pm ET
Viridian Therapeutics Leads in Thyroid Eye Disease Treatments: Superior Efficacy and Promising Pipeline Justify Buy Rating
Mar 01
1:00am ET
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potential
Feb 29
8:06am ET
Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN)
Feb 29
7:24am ET
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Catalyst Pharma (CPRX) and Viridian Therapeutics (VRDN)
Feb 29
7:22am ET
Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital
Feb 29
6:39am ET
Viridian Therapeutics: A Strong Buy on TED Treatment Prospects and Financial Stability
Feb 29
6:16am ET
Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo
Feb 29
5:40am ET
Buy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial Potential
Feb 28
8:49am ET
Viridian Therapeutics price target raised to $40 from $39 at Wedbush
Feb 28
7:23am ET
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Masimo (MASI) and Johnson & Johnson (JNJ)
Feb 28
7:15am ET
Buy Rating for Viridian Therapeutics Backed by Strong Financials and Promising Drug Candidate
Feb 28
7:10am ET
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)
Feb 28
7:09am ET
Viridian Therapeutics: A Promising Investment on the Brink of Key Milestones in Thyroid Eye Disease Treatment
Feb 28
6:50am ET
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN)
Feb 28
6:44am ET
Viridian Therapeutics price target lowered to $37 from $38 at JMP Securities
Feb 28
12:55am ET
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Drug Pipeline Progress and Robust Financial Position
Feb 27
4:08pm ET
Viridian Therapeutics expects cash to fund operations into second half of 2026
Feb 27
4:07pm ET
Viridian Therapeutics reports Q4 EPS ($1.35), consensus ($1.00)
Feb 16
8:06am ET
Viridian Therapeutics names Jennifer Tousignant chief legal officer
Jan 25
6:44am ET
Insider Trading: Viridian (NASDAQ:VRDN) Sees Huge Insider Buy
Jan 22
8:31am ET
Viridian Therapeutics price target lowered to $39 from $40 at Wedbush
Jan 17
10:45pm ET
Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00
Jan 17
4:05pm ET
Viridian announces offering of common stock, Series B preferred stock
Jan 12
7:36am ET
Spyre Therapeutics price target raised to $36 from $27 at Stifel
Jan 12
7:35am ET
Apogee Therapeutics price target raised to $46 from $34 at Stifel
Jan 11
1:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), Viridian Therapeutics (VRDN) and Blueprint Medicines (BPMC)
No recent news articles are available for VRDN
VRDN Financials
Key terms
Ad Feedback
VRDN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VRDN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range